ProQR Announces Third Quarter 2022 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today reported its financial and operating results for the third quarter ended September 30, 2022, and provided a business update.
Related news for (PRQR)
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR to Present at Upcoming Scientific and Industry Conferences
- Lilly and ProQR to Expand RNA Editing Collaboration
- Lilly and ProQR to Expand RNA Editing Collaboration
- ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform